OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Pulmonary Medicine is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Spirometry, computed tomography, comorbidities, oxygen therapy and other topics in chronic obstructive pulmonary disease and an update on silicosis	69
Bronchoscopic treatment of early-stage peripheral lung cancer	41
The persistent problem of persistent air-leaks: approach to management	32
Cardiac sarcoidosis and neurosarcoidosis – multidisciplinary approach for diagnosis	26
Thoracic computed tomography in the progressive fibrotic phenotype	26
Thoracic empyema: aetiology, diagnosis, treatment, and prevention	25
The role of PET in the management of sarcoidosis	25
Labelling and denominating lung toxicity effects of pesticides	25
Home monitoring in asthma: towards digital twins	23
The evolving role of radiological imaging in cystic fibrosis	22
Improving care in lung cancer surgery: a review of quality measures and evolving standards	21
Lung microbiome, gut–lung axis and chronic obstructive pulmonary disease	21
Evolving nutritional needs, obesity, and overweight status in cystic fibrosis	21
Digital outcome measures in pulmonary clinical trials	20
Direct oral anticoagulant use in special populations	18
Genetic background of pulmonary (vascular) diseases – how much is written in the codes?	18
The different facets of sickle cell disease-related pulmonary hypertension	18
The justification for the progressive fibrotic phenotype	18
Micro-RNA in obstructive sleep apnoea: biomarker of cardiovascular outcome?	17
Implementation of digital home monitoring and management of respiratory disease	17
Novel interventions on the tricuspid valve: how to consider the pulmonary circulation?	17
Disease-specific gaps within fungal respiratory tract infections: clinical features, diagnosis, and management in critically ill patients	16
Bronchoscopic diagnosis of peripheral lung lesions	16
The role of chest computed tomography in the evaluation and management of chronic obstructive pulmonary disease	16
Editorial: A future focus on cystic fibrosis in an era of uncertainty despite opportunity	16

Group 2 pulmonary hypertension: from diagnosis to treatment	16
Editorial introductions	15
Editorial introductions	14
Paediatric asthma - all that wheezes is not necessarily asthma - current diagnostic and management strategies	14
Asthma in pregnancy: a review of recent literature	14
Considerations and clinical management of infections in sarcoidosis	14
An update of palliative care in lung transplantation with a focus on symptoms, quality of life and functional outcomes	13
Co-morbid insomnia and sleep apnea (COMISA): recent research and future directions	13
Household air pollution and respiratory health in Africa: persistent risk and unchanged health burdens	13
Elexacaftor–tezacaftor–ivacaftor use after solid organ transplant	13
The future of clinical trials in idiopathic pulmonary fibrosis	13
Lung transplant referral considerations for individuals with cystic fibrosis	13
Casting light on the many facets of sarcoidosis	12
Progress for all: addressing disparities in sarcoidosis	11
Mechanisms relating to sleeping position to the endotypes of sleep disordered breathing	11
Cystic fibrosis liver disease in the post-modulator era	11
The emerging role of inorganic elements as potential antigens in sarcoidosis	11
The modern landscape of fertility, pregnancy, and parenthood in people with cystic fibrosis	11
Acute rejection post lung transplant	11
Sarcoidosis and frailty: recognizing factors that foster holistic resilience	11
Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice	11
Tobacco treatment in the setting of lung cancer screening	11
Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators	10
Utility of peak inspiratory flow measurement for dry powder inhaler use in chronic obstructive pulmonary disease	10
Digital inhalers for asthma management	10
Food for thought: optimal diet in patients with asthma and chronic obstructive pulmonary disease	10
Imaging in peripheral bronchoscopy	10
What causes cough in pulmonary fibrosis, and how should we treat it?	9
Patterns of progression in non-IPF fibrotic interstitial lung disease	9
Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators	9
Home monitoring of coronavirus disease 2019 patients in different phases of disease	9
Editorial: Are we ready for prime time?	9
Editorial: Silicosis, asbestos-related diseases, war-site exposures and a variety of topics in chronic obstructive pulmonary disease	9
Chronic obstructive pulmonary disease risk assessment tools: is one better than the others?	9
Mass gathering events and transmission of respiratory tract infections: updates pre and post COVID-19 lockdown	9
Novel insights in fibrotic pulmonary sarcoidosis	9
Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort	8
Editorial: COVID pandemic and Lung cancer: challenges lead to opportunities	8
Severe pulmonary toxicity associated with inhalation of pyrethroid-based domestic insecticides (Bop/Sapolio): a case series and literature review	8
Obstructive lung diseases burden and COVID-19 in developing countries: a perspective	8
Altered pharmacology and toxicology during ageing: implications for lung disease	8
Role of extracorporeal membrane oxygenation and surgical embolectomy in acute pulmonary embolism	8
Infection control in cystic fibrosis: evolving perspectives and challenges	8
Exhaled breath analysis in interstitial lung disease	8
Interventional pulmonology: reflection on the past, perfecting the present and innovating for the future	8
Multidisciplinary care in nonmalignant central airway obstruction	8
Effectiveness and safety of coronavirus disease 2019 vaccines	8
Epigenetics and aging: relevance for sleep medicine	7
Pediatric interventional bronchoscopy: from early limitations to achievable opportunities	7
Editorial: ‘What is your occupation?’: historical snippets	7

Telerehabilitation in pulmonary diseases	7
Right ventricular assessment in pulmonary hypertension	7
Risk stratification of indeterminate pulmonary nodules	7
Transbronchial biopsy vs. bronchoalveolar lavage in interstitial lung disease	7
The association of preexisting severe asthma with COVID-19 outcomes	7
Occupational exposures and sarcoidosis: current understanding and knowledge gaps	6
The changing landscape of infections in the lung transplant recipient	6
Military deployment-related respiratory problems: an update	6
Pre-chronic obstructive pulmonary disease: a pathophysiologic process or an opinion term?	6
The current understanding and future directions for sputum microbiome profiling in chronic obstructive pulmonary disease	6
Pulmonary rehabilitation in idiopathic pulmonary fibrosis	6
Advancing bacteriophages as a treatment of antibiotic-resistant bacterial pulmonary infections	6
Ergonomics in bronchoscopy	6
Approach to the hospitalized patient with pulmonary arterial hypertension	6
Advancements in airway stents: a comprehensive update	6
Bronchoscopic lung volume reduction in emphysema: a review	6
Adenotonsillectomy: the good, the bad and the unknown	6
Telehealth and virtual health monitoring in cystic fibrosis	6
Prader–Willi syndrome: an update	6
Long-term safety, durability of response, cessation and switching of biologics	6
Pulmonary embolism work-up in chronic obstructive pulmonary disease exacerbations: what is the best strategy for clinicians?	6
Pulmonary rehabilitation in a postcoronavirus disease 2019 world: feasibility, challenges, and solutions	6
Shifting gears: the search for group 3 pulmonary hypertension treatment	6
Rigid versus flexible bronchoscopy in interventional pulmonology: perspective from the master clinicians	6